Blog
RSS FeedPosted by Michael Wonder on 21 Nov 2019
Allogeneic hematopoietic cell transplantation and other expensive cellular therapies: a miracle for the few but off limits to many?
15 November 2019 - The number of patients undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of malignant and nonmalignant disorders ...
Posted by Michael Wonder on 20 Nov 2019
Life saving therapy denied to dying cop
20 November 2019 - Doctors at Sydney’s Royal Prince Alfred Hospital are refusing to treat a terminally ill cancer patient ...
Posted by Michael Wonder on 09 Nov 2019
Triumvira Immunologics announces fast track designation for its first TAC T-Cell therapeutic product candidate: TAC01-CD19
7 November 2019 - Designation confirms significant unmet need remains in DLBCL. ...
Posted by Michael Wonder on 06 Nov 2019
Innovation and access at the mercy of payment policy: the future of chimeric antigen receptor therapies
1 November 2019 - In 2017, the US FDA approved the first chimeric antigen receptor therapies (CAR-Ts), tisagenlecleucel and axicabtagene ...
Posted by Michael Wonder on 10 Oct 2019
FDA grants FX-322 fast track designation
10 October 2019 - The company also announced today that the U.S. FDA has granted fast track designation for FX-322. ...
Posted by Michael Wonder on 10 Oct 2019
Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...
Posted by Michael Wonder on 20 Sep 2019
SanBio granted regenerative medicine advanced therapy designation from the U.S. FDA for SB623 for the treatment of chronic neurological motor deficits secondary to traumatic brain injury
19 September 2019 - The SanBio Group today announced that the U.S. FDA has granted regenerative medicine advanced therapy designation ...
Posted by Michael Wonder on 11 Sep 2019
Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive
10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...
Posted by Michael Wonder on 27 Aug 2019
DiscGenics receives FDA fast track designation for disc degeneration cell therapy
26 August 2019 - DiscGenics today announced that the U.S. FDA has granted Fast Track designation for its investigational cell ...
Posted by Michael Wonder on 18 Aug 2019
Cancer patient David Downs working to bring treatment that helped him to NZ
18 August 2019 - There are those people who cheerfully refer to themselves as glass half-full types – and then ...
Posted by Michael Wonder on 07 Aug 2019
Trump Administration makes CAR T-Cell cancer therapy available to Medicare beneficiaries nationwide
7 August 2019 - Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely ...
Posted by Michael Wonder on 06 Aug 2019
ICER seeks public comment on proposed methods adaptations for assessments of potential cures and other transformative therapies
6 August 2019 - Proposed adaptations help manage increased uncertainty, capture new value dimensions for appraisal committee voting, and adopt a ...
Posted by Michael Wonder on 04 Aug 2019
Melbourne to pioneer free treatment to save sickest cancer kids
4 August 2019 - The nation’s youngest cancer patients, who had previously been forced to travel overseas for lifesaving treatment, will ...
Posted by Michael Wonder on 01 Aug 2019
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
30 July 2019 - Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by ...
Posted by Michael Wonder on 30 Jul 2019
CAR T-cell therapy: a microcosm for the challenges ahead in Medicare
29 July 2019 - The search for more effective and less toxic therapies for cancer has occupied scientists for decades. ...